Agios Pharmaceuticals Inc (STU:8AP)
€ 34.2 -3 (-8.06%) Market Cap: 1.93 Bil Enterprise Value: 1.03 Bil PE Ratio: 3.01 PB Ratio: 1.20 GF Score: 50/100

Agios Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 03:50PM GMT
Release Date Price: €37 (-2.43%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everybody, to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team.

The next presenting company, we have is Agios. And speaking on behalf of the company, we have CEO, Jackie Fouse. Before I turn it over to Jackie, just wanted to highlight to the listeners on the webcast that you can submit a question by the ask-a-question feature in the portal, and I'm happy to ask those questions on your behalf. Jackie?

Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director

Thanks, Anupam. Hi, everybody. Thank you for joining us for our Agios presentation at the conference today.

So back on December 21, we announced a 2-part change in our strategy, and it is something I'll cover with you today. We're very excited about where we're going at Agios and where we are with respect to leveraging the strengths that we've built up over our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot